Nutriband CEO Gareth Sheridan Named EY Entrepreneur of the Year 2025 Finalist

Gareth Sheridan, CEO of Nutriband Inc., has been selected as a finalist in the Established category of the 2025 EY Entrepreneur of the Year Awards, marking a significant milestone for the life sciences company. The recognition highlights Sheridan's leadership in transforming Nutriband from an early-stage startup to a publicly traded company focused on addressing critical challenges in pharmaceutical drug delivery.

As one of 27 Irish entrepreneurs recognized this year, Sheridan's selection reflects the company's innovative approach to solving complex medical challenges. The finalist group represents 24 companies generating over €1 billion in annual revenue, underscoring the prestigious nature of the award and the caliber of entrepreneurial talent being celebrated.

Nutriband's primary focus has been developing transdermal pharmaceutical products, with its lead product AVERSA™ designed to prevent misuse and abuse of opioid patches. This technology represents a critical advancement in pain management, addressing the ongoing challenges of drug abuse and accidental exposure.

The EY Entrepreneur of the Year program provides significant professional development opportunities for its finalists, including a CEO retreat in Japan. The ultimate winner will be announced at a gala event in November, offering substantial visibility and recognition for the selected entrepreneur and their company.

For human resources professionals and business leaders, Sheridan's nomination offers insights into the qualities that distinguish exceptional entrepreneurial leadership. These include strategic innovation, the ability to navigate complex industry challenges, and a commitment to developing solutions that can significantly impact public health and safety.

The recognition also signals Nutriband's potential for continued growth and innovation in the life sciences sector. By focusing on abuse-deterrent technologies, the company demonstrates a forward-thinking approach to pharmaceutical development that addresses critical societal needs.